cells mg Search Results


93
CLS Cell Lines Service GmbH dmem
Dmem, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/MG-63+Cells/pmc12365874-110-5-38
Average 93 stars, based on 1 article reviews
dmem - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc proteasome inhibitor mg132
Proteasome Inhibitor Mg132, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/MG-132/pm38502701-412-17-20
Average 96 stars, based on 1 article reviews
proteasome inhibitor mg132 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
CLS Cell Lines Service GmbH u251 cell line
Transcriptomic analysis of GPER+ or control samples. (A) Representative image of GPER protein expression in <t>U251</t> cells detected by Western blotting. n=3. (B) Clustering of GPER+ or control samples based on differentially expressed genes (│ FC│ > 1.7, p < 0.05, n=4). The cluster was visualized by Treeview. Green indicates a lower expression and red indicates a higher expression.
U251 Cell Line, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/U-251+MG+Cells/pmc13649380-129-0-6
Average 93 stars, based on 1 article reviews
u251 cell line - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Rockland Immunochemicals hek293 cells
Validation of preferential affinity . (a) GO molecular function term significance in the various sets of proteins inferred to bind preferentially one or several subtypes of nucleic acids. We observe the clear separation between molecular functions enriched in inferred DNA- and RNA-binding proteins. Color log-scale: red = P < 1E-15, light yellow = P < 0.01, gray = P ≥ 0.01. (b) Examples of affinity preferences of selected NABPs represented by P -values in the statistical analysis (table on left) and western blots in the experimental validation (right). We note the strong agreement between preferred versus non-preferred affinities in the statistics and the blots. (C20orf72 was purified with a Myc tag in <t>HEK293</t> cells instead of a specific antibody in HepG2 cells.) (c) Methylation specificity usually correlates with CG specificity, but UHRF1 and YB-1 were specific to mCG only in the statistical analysis (see reported P -values in the table on the left). Experimental validation confirmed their specificity (right); AIM2 was used as a DNA-binding non-specific control.
Hek293 Cells, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/HEK293+Whole+Cell+Lysate+MG-132+Treated/pmc04053969-198-9-17
Average 93 stars, based on 1 article reviews
hek293 cells - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

91
Revvity u87 mg red fluc cells
IC 50 for TMZ on cell viability in <t>U87</t> <t>MG-Red-FLuc</t> human glioblastoma cells by cell counts. The concentration-dependent inhibitory dose-curve data was plotted as log percentage inhibition normalized to controls with applied curve non-fit calculated using GraphPad Prism. Results are shown as the mean of at least three independent experiments ± SEM.
U87 Mg Red Fluc Cells, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/Bioware+Brite+Cell+Line+U87+MG-Red-FLuc/pmc10030813-74-27-30
Average 91 stars, based on 1 article reviews
u87 mg red fluc cells - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

94
MedChemExpress human serum albumin bound nafl
Explanatory diagram of the blood and normal brain kinetic study. Cohorts of study animals were administered (via tail vein) low-dose <t>NaFL,</t> high-dose NaFl, or pegylated-fluorescein (PEG-fluorescein) at 15, 30, 60, or 120 minutes before euthanasia. Blood and tissue specimens were then harvested and used to analyze the presence of different forms of fluorescein in various tissue/blood compartments. fl= fluorescein. Figure is available in color online only.
Human Serum Albumin Bound Nafl, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/Human+serum+albumin/pmc06995036-110-3-6
Average 94 stars, based on 1 article reviews
human serum albumin bound nafl - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology u87 glioblastoma cell line lysate
Explanatory diagram of the blood and normal brain kinetic study. Cohorts of study animals were administered (via tail vein) low-dose <t>NaFL,</t> high-dose NaFl, or pegylated-fluorescein (PEG-fluorescein) at 15, 30, 60, or 120 minutes before euthanasia. Blood and tissue specimens were then harvested and used to analyze the presence of different forms of fluorescein in various tissue/blood compartments. fl= fluorescein. Figure is available in color online only.
U87 Glioblastoma Cell Line Lysate, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/U-87+MG+Cell+Lysate/pmc05430958-312-5-33
Average 93 stars, based on 1 article reviews
u87 glioblastoma cell line lysate - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
CLS Cell Lines Service GmbH cell lines service 300363
Explanatory diagram of the blood and normal brain kinetic study. Cohorts of study animals were administered (via tail vein) low-dose <t>NaFL,</t> high-dose NaFl, or pegylated-fluorescein (PEG-fluorescein) at 15, 30, 60, or 120 minutes before euthanasia. Blood and tissue specimens were then harvested and used to analyze the presence of different forms of fluorescein in various tissue/blood compartments. fl= fluorescein. Figure is available in color online only.
Cell Lines Service 300363, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/U-138+MG+Cells/bio_rxiv__64898__2025__12__01__691550-33-24-24
Average 94 stars, based on 1 article reviews
cell lines service 300363 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
CLS Cell Lines Service GmbH t98g cells
Talaporfin (NPe6)-mediated photodynamic therapy (NPe6-PDT) induced proapoptotic Bcl-2 associated X protein (Bax) activation and caspase-dependent/independent cell death in glioblastoma (GBM) cells. ( a ) Human GBM cell lines <t>T98G</t> and U343MG were subjected to vehicle treatment (control), NPe6 treatment (μg·mL −1 ), laser treatment, or NPe6-PDT, as shown in the figure (see the Materials and Methods for detailed treatments). After 24 h, the mortality rate of the treated cells was assayed by the dye exclusion assay. ( b ) T98G and U343MG cells were subjected to vehicle treatment (control), NPe6-PDT (NPe6, 15 μg mL −1 ), or 5-fluorouracil (5-FU, 500 μM) treatment with or without z-VAD-FMK (a pan-caspase inhibitor; 100 μM) pretreatment for 2 h before laser irradiation ( A), as shown in the figure. After 24 h of laser irradiation, the mortality rate was assayed as described in the Materials and Methods. ( c ) T98G and U343MG cells were subjected to NPe6-PDT at the indicated NPe6 dose with pretreatment using vehicle or z-VAD-FMK (100 μM), as shown in the figure. After 24 h, the relative proportion of the mortality rates of z-VAD-FMK-sensitive and -insensitive cells in total cell death rate were calculated as described in the Materials and Methods. ( d ) T98G and U343MG cells were subjected to vehicle treatment (control), NPe6 treatment (15 μg·mL −1 ), laser treatment, or NPe6-PDT (NPe6 15 μg·mL −1 ), as shown in the figure. After 24 h, the cell lysates were subjected to in vitro protein crosslinking assay as described in the Materials and Methods, followed by immunoblotting using a primary antibody against Bax.
T98g Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/U-343+MG+Cells/pmc07761910-48-0-5
Average 92 stars, based on 1 article reviews
t98g cells - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

94
CLS Cell Lines Service GmbH human gbm cell line u 87
a Schematic of the synthesis and immobilization strategy for biotinylated CA4-prodrug ( 6 ), synthesized via sequential decoration of cTCO-bis-NHS ( 5 ). The biotin handle allows immobilization onto streptavidin-coated magnetic beads, forming a localized, iontronically activatable prodrug reservoir. IPs were positioned above the beads in a transwell insert <t>containing</t> <t>U-87</t> cells in the lower chamber. Grey pills indicate inactive (bound) drug, blue (colored) pills indicate active drug. b 3D-printed platform designed to precisely position iontronic devices in standard 96-well transwell plates. c Cell viability of U-87 cells after operating iontronic devices delivering 1 for 4 h at +20 nA (Active, n = 8) and at −20 nA (Reverse, n = 7) into transwells holding CA4-immobilized beads from ( a ). Points represent individual biological replicates; bars indicate mean ± SD. GC growth control (untreated, n = 32), “No Beads” = operation of iontronic devices delivering 1 at +20 nA, no beads in transwell present ( n = 6), “No Tz 1 ” = CA4-immobilized beads in transwell present with iontronic delivery of K + (0.1 M KCl) instead of Tz 1 ( n = 8). Statistical analysis was done via a Brown–Forsythe and Welch ANOVA tests (one-way) and Dunnett’s T3 multiple comparisons test. α = 0.05. p -values: GC vs. No Beads (ns) = 0.2377; GC vs. No Tz 1 (ns) = 0.3827; GC vs. Reverse, 4 h (ns) = 0.5739, GC vs. Active, 4 h (****) = <0.0001. Certain graphical elements in ( a ) were created in BioRender. Hecko, S. (2026) https://www.BioRender.com/z8yr1eu .
Human Gbm Cell Line U 87, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/U-87+MG+Cells/pmc13199424-191-1-15
Average 94 stars, based on 1 article reviews
human gbm cell line u 87 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
CLS Cell Lines Service GmbH u118mga
a Schematic of the synthesis and immobilization strategy for biotinylated CA4-prodrug ( 6 ), synthesized via sequential decoration of cTCO-bis-NHS ( 5 ). The biotin handle allows immobilization onto streptavidin-coated magnetic beads, forming a localized, iontronically activatable prodrug reservoir. IPs were positioned above the beads in a transwell insert <t>containing</t> <t>U-87</t> cells in the lower chamber. Grey pills indicate inactive (bound) drug, blue (colored) pills indicate active drug. b 3D-printed platform designed to precisely position iontronic devices in standard 96-well transwell plates. c Cell viability of U-87 cells after operating iontronic devices delivering 1 for 4 h at +20 nA (Active, n = 8) and at −20 nA (Reverse, n = 7) into transwells holding CA4-immobilized beads from ( a ). Points represent individual biological replicates; bars indicate mean ± SD. GC growth control (untreated, n = 32), “No Beads” = operation of iontronic devices delivering 1 at +20 nA, no beads in transwell present ( n = 6), “No Tz 1 ” = CA4-immobilized beads in transwell present with iontronic delivery of K + (0.1 M KCl) instead of Tz 1 ( n = 8). Statistical analysis was done via a Brown–Forsythe and Welch ANOVA tests (one-way) and Dunnett’s T3 multiple comparisons test. α = 0.05. p -values: GC vs. No Beads (ns) = 0.2377; GC vs. No Tz 1 (ns) = 0.3827; GC vs. Reverse, 4 h (ns) = 0.5739, GC vs. Active, 4 h (****) = <0.0001. Certain graphical elements in ( a ) were created in BioRender. Hecko, S. (2026) https://www.BioRender.com/z8yr1eu .
U118mga, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/U-118+MG+Cells/pmc08522845__oncotarget___12___2188___s001-273-0-1
Average 90 stars, based on 1 article reviews
u118mga - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

95
Chem Impex International chloramphenicol
a Schematic of the synthesis and immobilization strategy for biotinylated CA4-prodrug ( 6 ), synthesized via sequential decoration of cTCO-bis-NHS ( 5 ). The biotin handle allows immobilization onto streptavidin-coated magnetic beads, forming a localized, iontronically activatable prodrug reservoir. IPs were positioned above the beads in a transwell insert <t>containing</t> <t>U-87</t> cells in the lower chamber. Grey pills indicate inactive (bound) drug, blue (colored) pills indicate active drug. b 3D-printed platform designed to precisely position iontronic devices in standard 96-well transwell plates. c Cell viability of U-87 cells after operating iontronic devices delivering 1 for 4 h at +20 nA (Active, n = 8) and at −20 nA (Reverse, n = 7) into transwells holding CA4-immobilized beads from ( a ). Points represent individual biological replicates; bars indicate mean ± SD. GC growth control (untreated, n = 32), “No Beads” = operation of iontronic devices delivering 1 at +20 nA, no beads in transwell present ( n = 6), “No Tz 1 ” = CA4-immobilized beads in transwell present with iontronic delivery of K + (0.1 M KCl) instead of Tz 1 ( n = 8). Statistical analysis was done via a Brown–Forsythe and Welch ANOVA tests (one-way) and Dunnett’s T3 multiple comparisons test. α = 0.05. p -values: GC vs. No Beads (ns) = 0.2377; GC vs. No Tz 1 (ns) = 0.3827; GC vs. Reverse, 4 h (ns) = 0.5739, GC vs. Active, 4 h (****) = <0.0001. Certain graphical elements in ( a ) were created in BioRender. Hecko, S. (2026) https://www.BioRender.com/z8yr1eu .
Chloramphenicol, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cells+mg/Chloramphenicol/pm41773869-100-11-12
Average 95 stars, based on 1 article reviews
chloramphenicol - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


Transcriptomic analysis of GPER+ or control samples. (A) Representative image of GPER protein expression in U251 cells detected by Western blotting. n=3. (B) Clustering of GPER+ or control samples based on differentially expressed genes (│ FC│ > 1.7, p < 0.05, n=4). The cluster was visualized by Treeview. Green indicates a lower expression and red indicates a higher expression.

Journal: Frontiers in Endocrinology

Article Title: G-protein coupled estrogen receptor 1 (GPER1) expression improves survival of glioblastoma patients depending on sex and age: biological mechanisms and epigenetic regulation

doi: 10.3389/fendo.2026.1923928

Figure Lengend Snippet: Transcriptomic analysis of GPER+ or control samples. (A) Representative image of GPER protein expression in U251 cells detected by Western blotting. n=3. (B) Clustering of GPER+ or control samples based on differentially expressed genes (│ FC│ > 1.7, p < 0.05, n=4). The cluster was visualized by Treeview. Green indicates a lower expression and red indicates a higher expression.

Article Snippet: U251 cell line was purchased from Cytion (catalog number 300385, Cytion GmbH, Eppelheim, Germany) and maintained in Dulbecco’s modified eagle medium (DMEM) phenol red-free (Gibco) supplemented with 10% fetal bovine serum (FBS), 1% essential amino acids (Sigma-Aldrich), 0.5% non-essential amino acids (Sigma-Aldrich), 0.4% vitamins solution (Sigma-Aldrich), 1.25% sodium pyruvate (SigmaAldrich) and 1% streptomycin/penicillin (Sigma-Aldrich) at 37 °C in a humidified 5% CO 2 atmosphere.

Techniques: Analysis, Control, Expressing, Western Blot

Cell cycle impairment in GPER overexpressing U251 cells. Representative histogram of flow cytometry analyses displaying the distribution of control or GPER+ U251 cells in different phases of the cell cycle. Flow cytometry analysis quantifications are presented as the mean ± SD. n = 4. The level of significance was determined using Student’s t-test with ****indicates p < 0.0001, ***p < 0.001 and *p < 0.05.

Journal: Frontiers in Endocrinology

Article Title: G-protein coupled estrogen receptor 1 (GPER1) expression improves survival of glioblastoma patients depending on sex and age: biological mechanisms and epigenetic regulation

doi: 10.3389/fendo.2026.1923928

Figure Lengend Snippet: Cell cycle impairment in GPER overexpressing U251 cells. Representative histogram of flow cytometry analyses displaying the distribution of control or GPER+ U251 cells in different phases of the cell cycle. Flow cytometry analysis quantifications are presented as the mean ± SD. n = 4. The level of significance was determined using Student’s t-test with ****indicates p < 0.0001, ***p < 0.001 and *p < 0.05.

Article Snippet: U251 cell line was purchased from Cytion (catalog number 300385, Cytion GmbH, Eppelheim, Germany) and maintained in Dulbecco’s modified eagle medium (DMEM) phenol red-free (Gibco) supplemented with 10% fetal bovine serum (FBS), 1% essential amino acids (Sigma-Aldrich), 0.5% non-essential amino acids (Sigma-Aldrich), 0.4% vitamins solution (Sigma-Aldrich), 1.25% sodium pyruvate (SigmaAldrich) and 1% streptomycin/penicillin (Sigma-Aldrich) at 37 °C in a humidified 5% CO 2 atmosphere.

Techniques: Flow Cytometry, Control, Analysis

Validation of preferential affinity . (a) GO molecular function term significance in the various sets of proteins inferred to bind preferentially one or several subtypes of nucleic acids. We observe the clear separation between molecular functions enriched in inferred DNA- and RNA-binding proteins. Color log-scale: red = P < 1E-15, light yellow = P < 0.01, gray = P ≥ 0.01. (b) Examples of affinity preferences of selected NABPs represented by P -values in the statistical analysis (table on left) and western blots in the experimental validation (right). We note the strong agreement between preferred versus non-preferred affinities in the statistics and the blots. (C20orf72 was purified with a Myc tag in HEK293 cells instead of a specific antibody in HepG2 cells.) (c) Methylation specificity usually correlates with CG specificity, but UHRF1 and YB-1 were specific to mCG only in the statistical analysis (see reported P -values in the table on the left). Experimental validation confirmed their specificity (right); AIM2 was used as a DNA-binding non-specific control.

Journal: Genome Biology

Article Title: Experimental characterization of the human non-sequence-specific nucleic acid interactome

doi: 10.1186/gb-2013-14-7-r81

Figure Lengend Snippet: Validation of preferential affinity . (a) GO molecular function term significance in the various sets of proteins inferred to bind preferentially one or several subtypes of nucleic acids. We observe the clear separation between molecular functions enriched in inferred DNA- and RNA-binding proteins. Color log-scale: red = P < 1E-15, light yellow = P < 0.01, gray = P ≥ 0.01. (b) Examples of affinity preferences of selected NABPs represented by P -values in the statistical analysis (table on left) and western blots in the experimental validation (right). We note the strong agreement between preferred versus non-preferred affinities in the statistics and the blots. (C20orf72 was purified with a Myc tag in HEK293 cells instead of a specific antibody in HepG2 cells.) (c) Methylation specificity usually correlates with CG specificity, but UHRF1 and YB-1 were specific to mCG only in the statistical analysis (see reported P -values in the table on the left). Experimental validation confirmed their specificity (right); AIM2 was used as a DNA-binding non-specific control.

Article Snippet: Myc-tagged C20orf72, AIM2, UHRF1 and YB-1 were overexpressed in HEK293 cells and visualized by immunoblotting using anti-Myc-IRDye800 (Rockland Gilbertsville, PA, USA ).

Techniques: Biomarker Discovery, RNA Binding Assay, Western Blot, Purification, Methylation, Binding Assay, Control

IC 50 for TMZ on cell viability in U87 MG-Red-FLuc human glioblastoma cells by cell counts. The concentration-dependent inhibitory dose-curve data was plotted as log percentage inhibition normalized to controls with applied curve non-fit calculated using GraphPad Prism. Results are shown as the mean of at least three independent experiments ± SEM.

Journal: Scientific Reports

Article Title: Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models

doi: 10.1038/s41598-023-31811-5

Figure Lengend Snippet: IC 50 for TMZ on cell viability in U87 MG-Red-FLuc human glioblastoma cells by cell counts. The concentration-dependent inhibitory dose-curve data was plotted as log percentage inhibition normalized to controls with applied curve non-fit calculated using GraphPad Prism. Results are shown as the mean of at least three independent experiments ± SEM.

Article Snippet: To track tumor growth in an orthotopic mouse model for glioblastoma, we decided to use commercially available human cancer cells expressing a very bright red-shifted luciferase (Red-FLuc), U87-MG-Red-FLuc cells ( https://www.perkinelmer.com/product/ivisbrite-u87mg-red-f-luc-bw124577 ).

Techniques: Concentration Assay, Inhibition

In vitro effect of the isolated components and of assembled new gel formulations on Glioblastoma cells. ( a ) U87-MG-Red-FLuc cells were treated with cell medium (CTRL), mesoporous SiO 2 nanoparticles (SiO 2 ) and polycaprolactone microparticles (PCL) for 24 h, causing no significant reduction in viable cells number. ( b ) U87 MG-Red-FLuc cells were treated with cell medium (CTRL), the empty thermogel (THG), and the thermogels containing mesoporous SiO 2 nanoparticles (THG@SiO 2 ) and polycaprolactone microparticles (THG@PCL) for 24 h, causing no significant reduction in viable cells number. ( c ) TMZ-containing SiO 2 nanoparticles and PCL microparticles efficiently release active drug into the cell medium to induce cell death after 24 h treatment in U87 MG-Red-FLuc cells (*p < 0.05). ( d ) THG@SiO 2 -TMZ and THG@PCL-TMZ efficiently release active TMZ into the cell medium to induce cell death after 24 h treatment in U87-MG-Red-FLuc cells (* p < 0.05; ** p < 0.005).

Journal: Scientific Reports

Article Title: Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models

doi: 10.1038/s41598-023-31811-5

Figure Lengend Snippet: In vitro effect of the isolated components and of assembled new gel formulations on Glioblastoma cells. ( a ) U87-MG-Red-FLuc cells were treated with cell medium (CTRL), mesoporous SiO 2 nanoparticles (SiO 2 ) and polycaprolactone microparticles (PCL) for 24 h, causing no significant reduction in viable cells number. ( b ) U87 MG-Red-FLuc cells were treated with cell medium (CTRL), the empty thermogel (THG), and the thermogels containing mesoporous SiO 2 nanoparticles (THG@SiO 2 ) and polycaprolactone microparticles (THG@PCL) for 24 h, causing no significant reduction in viable cells number. ( c ) TMZ-containing SiO 2 nanoparticles and PCL microparticles efficiently release active drug into the cell medium to induce cell death after 24 h treatment in U87 MG-Red-FLuc cells (*p < 0.05). ( d ) THG@SiO 2 -TMZ and THG@PCL-TMZ efficiently release active TMZ into the cell medium to induce cell death after 24 h treatment in U87-MG-Red-FLuc cells (* p < 0.05; ** p < 0.005).

Article Snippet: To track tumor growth in an orthotopic mouse model for glioblastoma, we decided to use commercially available human cancer cells expressing a very bright red-shifted luciferase (Red-FLuc), U87-MG-Red-FLuc cells ( https://www.perkinelmer.com/product/ivisbrite-u87mg-red-f-luc-bw124577 ).

Techniques: In Vitro, Isolation

In vivo efficacy of TMZ-based therapeutic thermogels using a GBM resection and recurrence mouse model. ( a ) Experimental timeline for studying the in vivo anticancer activities of gel-based local glioblastoma treatments. Two independent experiments comparing empty THG with THG@SIO 2 -TMZ and THG@PCL-TMZ, respectively, were performed (n = 5). Results were next merged resulting in n = 8 for THG, n = 3 for THG@SIO 2 -TMZ and n = 4 for THG@PCL-TMZ, considering drop-outs due to the severity of the procedure. ( b ) Representative BLI images of mice bearing U87-MG-Red-FLuc implantation in the subcortical striatal region. After primary tumor resection, THG@SIO 2 -TMZ, THG@PCL-TMZ or empty THG were applied. ( c ) Tumor growth was directly related to the increment of luminescence signal normalized to baseline (day 2 after resection, corresponding to Time 0 in panels A and B) and recorded at days 7 (Time 1), 14 (Time 2) and 21 (Time 3) after resection, in THG, THG@SiO 2 -TMZ and THG@PCL-TMZ groups. Tumor growth was expressed as fold increase [Lum(tx)−Lum (t0)/Lum (t0)]. THG@SIO 2 -TMZ or THG@PCL-TMZ reduced tumor recurrences when compared to empty THG treatment (*p < 0.05; two-ways ANOVA p < 0.05). ( d ). Luminescence signals from control (empty THG) animals on day 21 are significantly higher (*p < 0.05; Kruskal–Wallis test p < 0.004). ( e ) Site of the resection in relation to the Paxinos representation of brain coronal section at the injection coordinate (− 0.5 mm). Representative images of H&E-stained brain sections collected 21 days after tumor resection and gel application from mice receiving either THG@SIO 2 -TMZ, THG@PCL-TMZ or empty THG (control animals) show the growth of the tumor mass to the areas adjacent to the cancer cells injection site.

Journal: Scientific Reports

Article Title: Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models

doi: 10.1038/s41598-023-31811-5

Figure Lengend Snippet: In vivo efficacy of TMZ-based therapeutic thermogels using a GBM resection and recurrence mouse model. ( a ) Experimental timeline for studying the in vivo anticancer activities of gel-based local glioblastoma treatments. Two independent experiments comparing empty THG with THG@SIO 2 -TMZ and THG@PCL-TMZ, respectively, were performed (n = 5). Results were next merged resulting in n = 8 for THG, n = 3 for THG@SIO 2 -TMZ and n = 4 for THG@PCL-TMZ, considering drop-outs due to the severity of the procedure. ( b ) Representative BLI images of mice bearing U87-MG-Red-FLuc implantation in the subcortical striatal region. After primary tumor resection, THG@SIO 2 -TMZ, THG@PCL-TMZ or empty THG were applied. ( c ) Tumor growth was directly related to the increment of luminescence signal normalized to baseline (day 2 after resection, corresponding to Time 0 in panels A and B) and recorded at days 7 (Time 1), 14 (Time 2) and 21 (Time 3) after resection, in THG, THG@SiO 2 -TMZ and THG@PCL-TMZ groups. Tumor growth was expressed as fold increase [Lum(tx)−Lum (t0)/Lum (t0)]. THG@SIO 2 -TMZ or THG@PCL-TMZ reduced tumor recurrences when compared to empty THG treatment (*p < 0.05; two-ways ANOVA p < 0.05). ( d ). Luminescence signals from control (empty THG) animals on day 21 are significantly higher (*p < 0.05; Kruskal–Wallis test p < 0.004). ( e ) Site of the resection in relation to the Paxinos representation of brain coronal section at the injection coordinate (− 0.5 mm). Representative images of H&E-stained brain sections collected 21 days after tumor resection and gel application from mice receiving either THG@SIO 2 -TMZ, THG@PCL-TMZ or empty THG (control animals) show the growth of the tumor mass to the areas adjacent to the cancer cells injection site.

Article Snippet: To track tumor growth in an orthotopic mouse model for glioblastoma, we decided to use commercially available human cancer cells expressing a very bright red-shifted luciferase (Red-FLuc), U87-MG-Red-FLuc cells ( https://www.perkinelmer.com/product/ivisbrite-u87mg-red-f-luc-bw124577 ).

Techniques: In Vivo, Injection, Staining

Explanatory diagram of the blood and normal brain kinetic study. Cohorts of study animals were administered (via tail vein) low-dose NaFL, high-dose NaFl, or pegylated-fluorescein (PEG-fluorescein) at 15, 30, 60, or 120 minutes before euthanasia. Blood and tissue specimens were then harvested and used to analyze the presence of different forms of fluorescein in various tissue/blood compartments. fl= fluorescein. Figure is available in color online only.

Journal: Journal of neurosurgery

Article Title: Elucidating the kinetics of sodium fluorescein for fluorescence guided surgery of glioma

doi: 10.3171/2018.4.JNS172644

Figure Lengend Snippet: Explanatory diagram of the blood and normal brain kinetic study. Cohorts of study animals were administered (via tail vein) low-dose NaFL, high-dose NaFl, or pegylated-fluorescein (PEG-fluorescein) at 15, 30, 60, or 120 minutes before euthanasia. Blood and tissue specimens were then harvested and used to analyze the presence of different forms of fluorescein in various tissue/blood compartments. fl= fluorescein. Figure is available in color online only.

Article Snippet: Dilutions of NaFl, human serum-albumin–bound NaFl (MedChem Express) and PEG-fluorescein were used as control samples in the gels.

Techniques:

Quantification of unbound and bound NaFl in the blood circulation. Gel electrophoresis images of NaFl in blood serum at different times after administration are presented in A–G; low-dose administration data are shown in A–C and high dose in D–G. In a given gel panel, the columns represent, from left to right, the following: control containing diluted stock unbound NaFl (NaFl alone), control containing stock NaFl prebound to albumin (NaFl+Albumin), and blood samples from each of 3 mice (m1, m2, and m3 [2 samples were run per mouse]). The dashed lines delineate bound NaFl (above the dotted line) from unbound NaFl (below the dashed line), which were separated by weight in the gel. The percentages of the total fluorescent signal originating from the unbound and bound NaFl, computed from the gel images, are shown in H and I. Table of p values showing the difference in the percentage of unbound fluorescein between low- and high-dose cohorts at 15, 30, and 60 minutes postadministration is shown in J. Figure is available in color online only.

Journal: Journal of neurosurgery

Article Title: Elucidating the kinetics of sodium fluorescein for fluorescence guided surgery of glioma

doi: 10.3171/2018.4.JNS172644

Figure Lengend Snippet: Quantification of unbound and bound NaFl in the blood circulation. Gel electrophoresis images of NaFl in blood serum at different times after administration are presented in A–G; low-dose administration data are shown in A–C and high dose in D–G. In a given gel panel, the columns represent, from left to right, the following: control containing diluted stock unbound NaFl (NaFl alone), control containing stock NaFl prebound to albumin (NaFl+Albumin), and blood samples from each of 3 mice (m1, m2, and m3 [2 samples were run per mouse]). The dashed lines delineate bound NaFl (above the dotted line) from unbound NaFl (below the dashed line), which were separated by weight in the gel. The percentages of the total fluorescent signal originating from the unbound and bound NaFl, computed from the gel images, are shown in H and I. Table of p values showing the difference in the percentage of unbound fluorescein between low- and high-dose cohorts at 15, 30, and 60 minutes postadministration is shown in J. Figure is available in color online only.

Article Snippet: Dilutions of NaFl, human serum-albumin–bound NaFl (MedChem Express) and PEG-fluorescein were used as control samples in the gels.

Techniques: Nucleic Acid Electrophoresis, Control

Unbound NaFl crosses the BBB and extravasates into normal brain tissue. A: Quantitation of unbound and bound NaFl detected in whole brain extracts calculated from gel electrophoresis (a.u. = arbitrary units). B: Table of p values showing the difference between the amount of unbound fluorescein in normal brain tissue between low- and high-dose cohorts at all corresponding time points (15, 30, and 60 minutes) after administration. C: Representative fluorescence photomicrographs of naïve brain tissue sections 15, 30, 60, and 120 minutes post–NaFl administration. Original magnification ×20; scale bar = 20 μm. The red structures indicate lectin-stained vessels and green fluorescence indicates NaFl (n = 3–4 mice/group).

Journal: Journal of neurosurgery

Article Title: Elucidating the kinetics of sodium fluorescein for fluorescence guided surgery of glioma

doi: 10.3171/2018.4.JNS172644

Figure Lengend Snippet: Unbound NaFl crosses the BBB and extravasates into normal brain tissue. A: Quantitation of unbound and bound NaFl detected in whole brain extracts calculated from gel electrophoresis (a.u. = arbitrary units). B: Table of p values showing the difference between the amount of unbound fluorescein in normal brain tissue between low- and high-dose cohorts at all corresponding time points (15, 30, and 60 minutes) after administration. C: Representative fluorescence photomicrographs of naïve brain tissue sections 15, 30, 60, and 120 minutes post–NaFl administration. Original magnification ×20; scale bar = 20 μm. The red structures indicate lectin-stained vessels and green fluorescence indicates NaFl (n = 3–4 mice/group).

Article Snippet: Dilutions of NaFl, human serum-albumin–bound NaFl (MedChem Express) and PEG-fluorescein were used as control samples in the gels.

Techniques: Quantitation Assay, Nucleic Acid Electrophoresis, Fluorescence, Staining

Superficial distribution of NaFl in the naive rodent brain. A: Schematic of mouse brain outlining ROIs (olfactory bulb, cerebrum, and cerebellum) analyzed for spatial and temporal distribution of NaFl. B: Representative fluorescence images of ex vivo naïve brains at different times after administration of low- or high-dose NaFl. C: Time-dependent NaFl fluorescence intensity in normal brain regions (n = 3–4 mice/time point/dose). D: Table of p values showing the difference in the amount of superficial fluorescein fluorescence between low- and high-dose experimental cohorts is exhibited. Figure is available in color online only.

Journal: Journal of neurosurgery

Article Title: Elucidating the kinetics of sodium fluorescein for fluorescence guided surgery of glioma

doi: 10.3171/2018.4.JNS172644

Figure Lengend Snippet: Superficial distribution of NaFl in the naive rodent brain. A: Schematic of mouse brain outlining ROIs (olfactory bulb, cerebrum, and cerebellum) analyzed for spatial and temporal distribution of NaFl. B: Representative fluorescence images of ex vivo naïve brains at different times after administration of low- or high-dose NaFl. C: Time-dependent NaFl fluorescence intensity in normal brain regions (n = 3–4 mice/time point/dose). D: Table of p values showing the difference in the amount of superficial fluorescein fluorescence between low- and high-dose experimental cohorts is exhibited. Figure is available in color online only.

Article Snippet: Dilutions of NaFl, human serum-albumin–bound NaFl (MedChem Express) and PEG-fluorescein were used as control samples in the gels.

Techniques: Olfactory, Fluorescence, Ex Vivo

Extravasation of NaFl from internal regions within the naïve brain. A: Representative fluorescence images of axial sections from the naïve midbrain in mice injected with a low or high dose of NaFl at different time points after administration. B: Time-dependent fluorescence intensity in subregions (cortex, parenchyma, and ventricles) of axial cross sections from naïve rodent brains (n = 3–4 mice/time point/dose). C: Table displaying p values from the comparison of fluorescein fluorescence in brain subregions (cortex, parenchyma, and ventricular regions) in low-versus high-dose experimental cohorts. Figure is available in color online only.

Journal: Journal of neurosurgery

Article Title: Elucidating the kinetics of sodium fluorescein for fluorescence guided surgery of glioma

doi: 10.3171/2018.4.JNS172644

Figure Lengend Snippet: Extravasation of NaFl from internal regions within the naïve brain. A: Representative fluorescence images of axial sections from the naïve midbrain in mice injected with a low or high dose of NaFl at different time points after administration. B: Time-dependent fluorescence intensity in subregions (cortex, parenchyma, and ventricles) of axial cross sections from naïve rodent brains (n = 3–4 mice/time point/dose). C: Table displaying p values from the comparison of fluorescein fluorescence in brain subregions (cortex, parenchyma, and ventricular regions) in low-versus high-dose experimental cohorts. Figure is available in color online only.

Article Snippet: Dilutions of NaFl, human serum-albumin–bound NaFl (MedChem Express) and PEG-fluorescein were used as control samples in the gels.

Techniques: Fluorescence, Injection, Comparison

Pegylated-fluorescein administration results in reduced accumulation in normal brain tissue. A: Agarose gels of PEG-fluorescein in the blood. Similar to Fig. 3, the columns represent, from left to right, the following: control containing diluted stock unbound NaFl (NaFl alone), control containing stock NaFl prebound to albumin (NaFl+Albumin), PEG-fluorescein control, and fluorescence signals from blood samples from each of 3 mice (m1, m2, and m3 (2 samples were run per mouse]). B: Temporal behavior of pegylated-fluorescein in the blood, computed from the gels is displayed. C: Representative fluorescence images of whole brain surface distribution of pegylated-fluorescein and the fluorescence intensity over time in superficial brain regions (olfactory bulb, cerebrum, and cerebellum) for pegylated-fluorescein. D: Fluorescence axial sections of ex vivo brain samples postadministration of PEG-fluorescein and the fluorescence intensity of PEG-fluorescein in the internal brain subregions (cortex, parenchyma and ventricular regions) measured from brain slices. The pegylated form shows much lower transport into normal brain tissue. All scales (color scales and y-axis in quantitative graphs) were set to provide direct comparison to low-dose NaFl cohorts in Figs. 4B and ​andCC and ​and5A5A and ​andB.B. Figure is available in color online only.

Journal: Journal of neurosurgery

Article Title: Elucidating the kinetics of sodium fluorescein for fluorescence guided surgery of glioma

doi: 10.3171/2018.4.JNS172644

Figure Lengend Snippet: Pegylated-fluorescein administration results in reduced accumulation in normal brain tissue. A: Agarose gels of PEG-fluorescein in the blood. Similar to Fig. 3, the columns represent, from left to right, the following: control containing diluted stock unbound NaFl (NaFl alone), control containing stock NaFl prebound to albumin (NaFl+Albumin), PEG-fluorescein control, and fluorescence signals from blood samples from each of 3 mice (m1, m2, and m3 (2 samples were run per mouse]). B: Temporal behavior of pegylated-fluorescein in the blood, computed from the gels is displayed. C: Representative fluorescence images of whole brain surface distribution of pegylated-fluorescein and the fluorescence intensity over time in superficial brain regions (olfactory bulb, cerebrum, and cerebellum) for pegylated-fluorescein. D: Fluorescence axial sections of ex vivo brain samples postadministration of PEG-fluorescein and the fluorescence intensity of PEG-fluorescein in the internal brain subregions (cortex, parenchyma and ventricular regions) measured from brain slices. The pegylated form shows much lower transport into normal brain tissue. All scales (color scales and y-axis in quantitative graphs) were set to provide direct comparison to low-dose NaFl cohorts in Figs. 4B and ​andCC and ​and5A5A and ​andB.B. Figure is available in color online only.

Article Snippet: Dilutions of NaFl, human serum-albumin–bound NaFl (MedChem Express) and PEG-fluorescein were used as control samples in the gels.

Techniques: Control, Fluorescence, Olfactory, Ex Vivo, Comparison

Pegylated-fluorescein and NaFl in glioma-bearing brains. A: Representative fluorescence images of axial slices of excised brains 60 minutes after administration of NaFl or PEG-fluorescein (true tumors are outlined with blue dashed line). B: Tumor-to–contralateral normal brain tissue contrast for NaFl and PEG-fluorescein. C: Fluorescence signal intensity in tumor and normal regions. *p < 0.05; **p < 0.005 (n = 4 mice per cohort).

Journal: Journal of neurosurgery

Article Title: Elucidating the kinetics of sodium fluorescein for fluorescence guided surgery of glioma

doi: 10.3171/2018.4.JNS172644

Figure Lengend Snippet: Pegylated-fluorescein and NaFl in glioma-bearing brains. A: Representative fluorescence images of axial slices of excised brains 60 minutes after administration of NaFl or PEG-fluorescein (true tumors are outlined with blue dashed line). B: Tumor-to–contralateral normal brain tissue contrast for NaFl and PEG-fluorescein. C: Fluorescence signal intensity in tumor and normal regions. *p < 0.05; **p < 0.005 (n = 4 mice per cohort).

Article Snippet: Dilutions of NaFl, human serum-albumin–bound NaFl (MedChem Express) and PEG-fluorescein were used as control samples in the gels.

Techniques: Fluorescence

Talaporfin (NPe6)-mediated photodynamic therapy (NPe6-PDT) induced proapoptotic Bcl-2 associated X protein (Bax) activation and caspase-dependent/independent cell death in glioblastoma (GBM) cells. ( a ) Human GBM cell lines T98G and U343MG were subjected to vehicle treatment (control), NPe6 treatment (μg·mL −1 ), laser treatment, or NPe6-PDT, as shown in the figure (see the Materials and Methods for detailed treatments). After 24 h, the mortality rate of the treated cells was assayed by the dye exclusion assay. ( b ) T98G and U343MG cells were subjected to vehicle treatment (control), NPe6-PDT (NPe6, 15 μg mL −1 ), or 5-fluorouracil (5-FU, 500 μM) treatment with or without z-VAD-FMK (a pan-caspase inhibitor; 100 μM) pretreatment for 2 h before laser irradiation ( A), as shown in the figure. After 24 h of laser irradiation, the mortality rate was assayed as described in the Materials and Methods. ( c ) T98G and U343MG cells were subjected to NPe6-PDT at the indicated NPe6 dose with pretreatment using vehicle or z-VAD-FMK (100 μM), as shown in the figure. After 24 h, the relative proportion of the mortality rates of z-VAD-FMK-sensitive and -insensitive cells in total cell death rate were calculated as described in the Materials and Methods. ( d ) T98G and U343MG cells were subjected to vehicle treatment (control), NPe6 treatment (15 μg·mL −1 ), laser treatment, or NPe6-PDT (NPe6 15 μg·mL −1 ), as shown in the figure. After 24 h, the cell lysates were subjected to in vitro protein crosslinking assay as described in the Materials and Methods, followed by immunoblotting using a primary antibody against Bax.

Journal: Cancers

Article Title: Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation

doi: 10.3390/cancers12123641

Figure Lengend Snippet: Talaporfin (NPe6)-mediated photodynamic therapy (NPe6-PDT) induced proapoptotic Bcl-2 associated X protein (Bax) activation and caspase-dependent/independent cell death in glioblastoma (GBM) cells. ( a ) Human GBM cell lines T98G and U343MG were subjected to vehicle treatment (control), NPe6 treatment (μg·mL −1 ), laser treatment, or NPe6-PDT, as shown in the figure (see the Materials and Methods for detailed treatments). After 24 h, the mortality rate of the treated cells was assayed by the dye exclusion assay. ( b ) T98G and U343MG cells were subjected to vehicle treatment (control), NPe6-PDT (NPe6, 15 μg mL −1 ), or 5-fluorouracil (5-FU, 500 μM) treatment with or without z-VAD-FMK (a pan-caspase inhibitor; 100 μM) pretreatment for 2 h before laser irradiation ( A), as shown in the figure. After 24 h of laser irradiation, the mortality rate was assayed as described in the Materials and Methods. ( c ) T98G and U343MG cells were subjected to NPe6-PDT at the indicated NPe6 dose with pretreatment using vehicle or z-VAD-FMK (100 μM), as shown in the figure. After 24 h, the relative proportion of the mortality rates of z-VAD-FMK-sensitive and -insensitive cells in total cell death rate were calculated as described in the Materials and Methods. ( d ) T98G and U343MG cells were subjected to vehicle treatment (control), NPe6 treatment (15 μg·mL −1 ), laser treatment, or NPe6-PDT (NPe6 15 μg·mL −1 ), as shown in the figure. After 24 h, the cell lysates were subjected to in vitro protein crosslinking assay as described in the Materials and Methods, followed by immunoblotting using a primary antibody against Bax.

Article Snippet: T98G cells were obtained from Cell Lines Service (#300365) and U343MG cells from the American Type Culture Collection (#CRL-1690).

Techniques: Activation Assay, Control, Exclusion Assay, Irradiation, In Vitro, Western Blot

NPe6-PDT-induced cell death is mediated by the PARP1 activation-mediated activation of the mitochondrial proapoptotic Bcl-2 family proteins. ( a ) T98G and U343MG cells were treated as shown in D. After 24 h, the lysates of these treated cells were analyzed by immunoblotting using the indicated primary antibodies (Upper). GAPDH antibodies were used to confirm the amounts of protein loaded. The relative PARP activity of the equally treated cells (control = 1) was also demonstrated (Lower, * p < 0.01). ( b ) T98G and U343MG cells were subjected to NPe6-PDT (NPe6, 15 μg·mL −1 ) in the presence or absence of pretreatment with the vehicle, z-VAD-FMK (100 μM), 3-aminobenzamide (3-ABA, a PARP inhibitor, 3 mM), or PJ34 (a PARP inhibitor, 15 μM), as shown in the figure. After 24 h, the mortality rate of all treated cells was determined. * p < 0.01. ( c ) T98G and U343MG cells were subjected to NPe6-PDT (NPe6, 15 μg·mL −1 ) in the presence or absence of pretreatment with vehicle, 3-ABA (3 mM), or PJ34 (15 μM), as shown in the figure. After 24 h, the lysates of all these treated cells were separated into the mitochondria-enriched membrane fraction, cytosolic fraction, and nuclear fraction, as described in the Materials and Methods. The fractionated cell lysates as well as whole-cell lysates were analyzed by immunoblotting using the indicated primary antibodies. Antibodies against GAPDH (cytosolic fraction marker), ATP5H (mitochondrial fraction marker), and c-Myc (nuclear fraction marker) were used to confirm the amount of proteins loaded in each fraction. ( d ) T98G and U343MG cells were treated with siRNAs as indicated. After 48 h, these cells were further subjected to NPe6-PDT (NPe6, 15 μg mL −1 ) in the presence or absence of pretreatment with vehicle, 3-ABA (3 mM), or PJ34 (15 μM), as shown in the figure. After 24 h, the cell death rate of all treated cells was calculated. * p < 0.01.

Journal: Cancers

Article Title: Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation

doi: 10.3390/cancers12123641

Figure Lengend Snippet: NPe6-PDT-induced cell death is mediated by the PARP1 activation-mediated activation of the mitochondrial proapoptotic Bcl-2 family proteins. ( a ) T98G and U343MG cells were treated as shown in D. After 24 h, the lysates of these treated cells were analyzed by immunoblotting using the indicated primary antibodies (Upper). GAPDH antibodies were used to confirm the amounts of protein loaded. The relative PARP activity of the equally treated cells (control = 1) was also demonstrated (Lower, * p < 0.01). ( b ) T98G and U343MG cells were subjected to NPe6-PDT (NPe6, 15 μg·mL −1 ) in the presence or absence of pretreatment with the vehicle, z-VAD-FMK (100 μM), 3-aminobenzamide (3-ABA, a PARP inhibitor, 3 mM), or PJ34 (a PARP inhibitor, 15 μM), as shown in the figure. After 24 h, the mortality rate of all treated cells was determined. * p < 0.01. ( c ) T98G and U343MG cells were subjected to NPe6-PDT (NPe6, 15 μg·mL −1 ) in the presence or absence of pretreatment with vehicle, 3-ABA (3 mM), or PJ34 (15 μM), as shown in the figure. After 24 h, the lysates of all these treated cells were separated into the mitochondria-enriched membrane fraction, cytosolic fraction, and nuclear fraction, as described in the Materials and Methods. The fractionated cell lysates as well as whole-cell lysates were analyzed by immunoblotting using the indicated primary antibodies. Antibodies against GAPDH (cytosolic fraction marker), ATP5H (mitochondrial fraction marker), and c-Myc (nuclear fraction marker) were used to confirm the amount of proteins loaded in each fraction. ( d ) T98G and U343MG cells were treated with siRNAs as indicated. After 48 h, these cells were further subjected to NPe6-PDT (NPe6, 15 μg mL −1 ) in the presence or absence of pretreatment with vehicle, 3-ABA (3 mM), or PJ34 (15 μM), as shown in the figure. After 24 h, the cell death rate of all treated cells was calculated. * p < 0.01.

Article Snippet: T98G cells were obtained from Cell Lines Service (#300365) and U343MG cells from the American Type Culture Collection (#CRL-1690).

Techniques: Activation Assay, Western Blot, Activity Assay, Control, Membrane, Marker

Enhanced extracellular regulated kinase1/2 (ERK1/2) activation positively regulates the resistance of GBM (NPe6-PDT-R) cells to NPe6-PDT-induced cell death via the suppression of Bax activation. ( a ) Control, as well as NPe6-PDT-R T98G and U343MG cells were subjected to NPe6-PDT (NPe6, 15 μg·mL −1 ). After 24 h, the mortality rate of these treated cells was calculated (upper, * p < 0.01). Whole-cell lysates of control cells and equally treated cells subjected to in vitro crosslinking assay were analyzed by immunoblotting using the indicated primary antibodies (lower). ( b ) Lysates of control cells as well as those of NPe6-PDT-R T98G and U343MG cells were analyzed by immunoblotting using the indicated primary antibodies. ( c ) NPe6-PDT-R T98G and U343MG cells were subjected to NPe6-PDT (NPe6, 15 μg·mL −1 ), along with treatment with the vehicle or the indicated dose of trametinib. After 24 h, the lysates of crosslinked treated cells were analyzed by immunoblotting using a primary antibody against Bax. ( d ) Control cells, as well as NPe6-PDT-R T98G and U343MG cells were subjected to NPe6-PDT (NPe6, 15 μg·mL −1 ) in the presence or absence of pretreatment with the vehicle or the indicated dose of trametinib, as shown in the figure. After 24 h, the cell death rate of all treated cells was determined. * p < 0.01.

Journal: Cancers

Article Title: Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation

doi: 10.3390/cancers12123641

Figure Lengend Snippet: Enhanced extracellular regulated kinase1/2 (ERK1/2) activation positively regulates the resistance of GBM (NPe6-PDT-R) cells to NPe6-PDT-induced cell death via the suppression of Bax activation. ( a ) Control, as well as NPe6-PDT-R T98G and U343MG cells were subjected to NPe6-PDT (NPe6, 15 μg·mL −1 ). After 24 h, the mortality rate of these treated cells was calculated (upper, * p < 0.01). Whole-cell lysates of control cells and equally treated cells subjected to in vitro crosslinking assay were analyzed by immunoblotting using the indicated primary antibodies (lower). ( b ) Lysates of control cells as well as those of NPe6-PDT-R T98G and U343MG cells were analyzed by immunoblotting using the indicated primary antibodies. ( c ) NPe6-PDT-R T98G and U343MG cells were subjected to NPe6-PDT (NPe6, 15 μg·mL −1 ), along with treatment with the vehicle or the indicated dose of trametinib. After 24 h, the lysates of crosslinked treated cells were analyzed by immunoblotting using a primary antibody against Bax. ( d ) Control cells, as well as NPe6-PDT-R T98G and U343MG cells were subjected to NPe6-PDT (NPe6, 15 μg·mL −1 ) in the presence or absence of pretreatment with the vehicle or the indicated dose of trametinib, as shown in the figure. After 24 h, the cell death rate of all treated cells was determined. * p < 0.01.

Article Snippet: T98G cells were obtained from Cell Lines Service (#300365) and U343MG cells from the American Type Culture Collection (#CRL-1690).

Techniques: Activation Assay, Control, In Vitro, Western Blot

Enhanced migration of NPe6-PDT-R cells is regulated by enhanced ERK1/2 activation. ( A ) Control and NPe6-PDT-R T98G and U343MG cells were photographed under a phase-contrast microscope (×400). Scale bar, 10 μm. ( a ) T98G and U343MG cells were subjected to vehicle treatment (control), NPe6 treatment (15 μg·mL −1 ), laser treatment, or NPe6-PDT (NPe6, 15 μg·mL −1 ), as shown in the figure. Migration of these treated cells was assayed by the transwell assay at the indicated time points. * p < 0.01. ( b ) T98G and U343MG cells were subjected to laser treatment or NPe6-PDT (NPe6, 15 μg·mL −1 ) as shown in the figure. Then, the lysates of all treated cells at the indicated time points after treatment were analyzed by immunoblotting using the indicated antibodies. ( c ) NPe6-PDT-R T98G and U343MG cells were treated with vehicle, U0126 (MEK1/2 inhibitor; 10 mM), or trametinib (10 μM), as shown in the figure. After 24 h, the migration of all treated cells was assayed by the transwell assay (upper, * p < 0.01), and the lysates of the equally treated cells were analyzed by immunoblotting using the indicated primary antibodies (lower). ( d ) NPe6-PDT-R T98G and U343MG cells were treated as shown in d. The migration abilities of all treated cells were analyzed using the Incucyte system, as described in the Materials and Methods. * p < 0.01.

Journal: Cancers

Article Title: Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation

doi: 10.3390/cancers12123641

Figure Lengend Snippet: Enhanced migration of NPe6-PDT-R cells is regulated by enhanced ERK1/2 activation. ( A ) Control and NPe6-PDT-R T98G and U343MG cells were photographed under a phase-contrast microscope (×400). Scale bar, 10 μm. ( a ) T98G and U343MG cells were subjected to vehicle treatment (control), NPe6 treatment (15 μg·mL −1 ), laser treatment, or NPe6-PDT (NPe6, 15 μg·mL −1 ), as shown in the figure. Migration of these treated cells was assayed by the transwell assay at the indicated time points. * p < 0.01. ( b ) T98G and U343MG cells were subjected to laser treatment or NPe6-PDT (NPe6, 15 μg·mL −1 ) as shown in the figure. Then, the lysates of all treated cells at the indicated time points after treatment were analyzed by immunoblotting using the indicated antibodies. ( c ) NPe6-PDT-R T98G and U343MG cells were treated with vehicle, U0126 (MEK1/2 inhibitor; 10 mM), or trametinib (10 μM), as shown in the figure. After 24 h, the migration of all treated cells was assayed by the transwell assay (upper, * p < 0.01), and the lysates of the equally treated cells were analyzed by immunoblotting using the indicated primary antibodies (lower). ( d ) NPe6-PDT-R T98G and U343MG cells were treated as shown in d. The migration abilities of all treated cells were analyzed using the Incucyte system, as described in the Materials and Methods. * p < 0.01.

Article Snippet: T98G cells were obtained from Cell Lines Service (#300365) and U343MG cells from the American Type Culture Collection (#CRL-1690).

Techniques: Migration, Activation Assay, Control, Microscopy, Transwell Assay, Western Blot

Invasion of NPe6-PDT-R cells is augmented in an ERK1/2 activation-dependent manner, but extracellular matrix degradation in NPe6-PDT-R cells is upregulated independent of ERK1/2 activation. ( a ) U343MG cells were subjected to vehicle treatment, NPe6 treatment (15 μg·mL −1 ), laser treatment, or NPe6-PDT (NPe6, 15 μg·mL −1 ) as shown in the figure. After 3 days, these cells were subjected to the invadopodia assay as described in the Materials and Methods. Representative fluorescence images of confocal microscopy (upper) [red fluorescence, phalloidin (actin); blue fluorescence, DAPI (nucleus); green fluorescence, FITC-gelatin] and invadopodia formation (lower, * p < 0.01) were examined. Arrowhead denotes degradation sites on the gelatin matrix. ( b ) U343MG cells were subjected to vehicle treatment (control) and/or NPe6-PDT (NPe6, 15 μg·mL −1 ). After 3 days, the cells were subjected to invadopodia assay with or without trametinib pretreatment (10 μM) for 12 h, and the results are shown in A. Arrowheads denote degradation sites on the gelatin matrix. * p < 0.01. ( c ) T98G and U343MG cells were subjected to vehicle treatment (control) or NPe6-PDT (NPe6-PDT-R, NPe6, 15 μg·mL −1 ). After 5 days, the cells were subjected to transwell invasion assay with vehicle, trametinib (DMSO), or trametinib (10 μM) pretreatment for 12 h, as described in the Materials and Methods. * p < 0.01.

Journal: Cancers

Article Title: Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation

doi: 10.3390/cancers12123641

Figure Lengend Snippet: Invasion of NPe6-PDT-R cells is augmented in an ERK1/2 activation-dependent manner, but extracellular matrix degradation in NPe6-PDT-R cells is upregulated independent of ERK1/2 activation. ( a ) U343MG cells were subjected to vehicle treatment, NPe6 treatment (15 μg·mL −1 ), laser treatment, or NPe6-PDT (NPe6, 15 μg·mL −1 ) as shown in the figure. After 3 days, these cells were subjected to the invadopodia assay as described in the Materials and Methods. Representative fluorescence images of confocal microscopy (upper) [red fluorescence, phalloidin (actin); blue fluorescence, DAPI (nucleus); green fluorescence, FITC-gelatin] and invadopodia formation (lower, * p < 0.01) were examined. Arrowhead denotes degradation sites on the gelatin matrix. ( b ) U343MG cells were subjected to vehicle treatment (control) and/or NPe6-PDT (NPe6, 15 μg·mL −1 ). After 3 days, the cells were subjected to invadopodia assay with or without trametinib pretreatment (10 μM) for 12 h, and the results are shown in A. Arrowheads denote degradation sites on the gelatin matrix. * p < 0.01. ( c ) T98G and U343MG cells were subjected to vehicle treatment (control) or NPe6-PDT (NPe6-PDT-R, NPe6, 15 μg·mL −1 ). After 5 days, the cells were subjected to transwell invasion assay with vehicle, trametinib (DMSO), or trametinib (10 μM) pretreatment for 12 h, as described in the Materials and Methods. * p < 0.01.

Article Snippet: T98G cells were obtained from Cell Lines Service (#300365) and U343MG cells from the American Type Culture Collection (#CRL-1690).

Techniques: Activation Assay, Invadopodia Assay, Fluorescence, Confocal Microscopy, Control, Transwell Invasion Assay

a Schematic of the synthesis and immobilization strategy for biotinylated CA4-prodrug ( 6 ), synthesized via sequential decoration of cTCO-bis-NHS ( 5 ). The biotin handle allows immobilization onto streptavidin-coated magnetic beads, forming a localized, iontronically activatable prodrug reservoir. IPs were positioned above the beads in a transwell insert containing U-87 cells in the lower chamber. Grey pills indicate inactive (bound) drug, blue (colored) pills indicate active drug. b 3D-printed platform designed to precisely position iontronic devices in standard 96-well transwell plates. c Cell viability of U-87 cells after operating iontronic devices delivering 1 for 4 h at +20 nA (Active, n = 8) and at −20 nA (Reverse, n = 7) into transwells holding CA4-immobilized beads from ( a ). Points represent individual biological replicates; bars indicate mean ± SD. GC growth control (untreated, n = 32), “No Beads” = operation of iontronic devices delivering 1 at +20 nA, no beads in transwell present ( n = 6), “No Tz 1 ” = CA4-immobilized beads in transwell present with iontronic delivery of K + (0.1 M KCl) instead of Tz 1 ( n = 8). Statistical analysis was done via a Brown–Forsythe and Welch ANOVA tests (one-way) and Dunnett’s T3 multiple comparisons test. α = 0.05. p -values: GC vs. No Beads (ns) = 0.2377; GC vs. No Tz 1 (ns) = 0.3827; GC vs. Reverse, 4 h (ns) = 0.5739, GC vs. Active, 4 h (****) = <0.0001. Certain graphical elements in ( a ) were created in BioRender. Hecko, S. (2026) https://www.BioRender.com/z8yr1eu .

Journal: Nature Communications

Article Title: Iontronic click-to-release enables electrically controlled delivery of drugs and biomolecules beyond charge and size limitations

doi: 10.1038/s41467-026-70985-0

Figure Lengend Snippet: a Schematic of the synthesis and immobilization strategy for biotinylated CA4-prodrug ( 6 ), synthesized via sequential decoration of cTCO-bis-NHS ( 5 ). The biotin handle allows immobilization onto streptavidin-coated magnetic beads, forming a localized, iontronically activatable prodrug reservoir. IPs were positioned above the beads in a transwell insert containing U-87 cells in the lower chamber. Grey pills indicate inactive (bound) drug, blue (colored) pills indicate active drug. b 3D-printed platform designed to precisely position iontronic devices in standard 96-well transwell plates. c Cell viability of U-87 cells after operating iontronic devices delivering 1 for 4 h at +20 nA (Active, n = 8) and at −20 nA (Reverse, n = 7) into transwells holding CA4-immobilized beads from ( a ). Points represent individual biological replicates; bars indicate mean ± SD. GC growth control (untreated, n = 32), “No Beads” = operation of iontronic devices delivering 1 at +20 nA, no beads in transwell present ( n = 6), “No Tz 1 ” = CA4-immobilized beads in transwell present with iontronic delivery of K + (0.1 M KCl) instead of Tz 1 ( n = 8). Statistical analysis was done via a Brown–Forsythe and Welch ANOVA tests (one-way) and Dunnett’s T3 multiple comparisons test. α = 0.05. p -values: GC vs. No Beads (ns) = 0.2377; GC vs. No Tz 1 (ns) = 0.3827; GC vs. Reverse, 4 h (ns) = 0.5739, GC vs. Active, 4 h (****) = <0.0001. Certain graphical elements in ( a ) were created in BioRender. Hecko, S. (2026) https://www.BioRender.com/z8yr1eu .

Article Snippet: The human GBM cell line U-87 (provided by the MUG Cell Bank, catalogue no. 300367, CLS) was cultured at 37 °C and 5% CO 2 in Eagle’s minimum essential medium (E-MEM) containing 10% fetal bovine serum (FBS), 4.5 g/L glucose, 2 mM L -glutamine, and 1% MEM Non-Essential Amino Acids.

Techniques: Synthesized, Magnetic Beads, Control

a Schematic overview of the bioorthogonal click-to-release (C2R) cascade of CA4-prodrug: Aminoethyl tetrazine (Tz 1 ) triggers the release of the cytotoxic agent combretastatin A-4 ( CA4 ) from sulfo-cTCO-DMEDA-CA4 ( 4 ) via a tetrazine-triggered elimination from TCO caged payload and self-immolation. b Dose-dependent cell viability of human glioblastoma cell line U-87 after 72 h incubation with the key components of the C2R reaction. Data represent mean ± SD of n = 3 independent biological replicates. Curves were fit using four-parameter logistic regression. Prodrug 4 (0.01–1000 nM, grey curve); parent CA4 (0.01–1000 nM, blue curve); released CA4 (0.01–1000 nM 4 + 5 µM 1, dashed blue curve); Tz 1 (5 µM, purple data point). c Cell viability of U-87 cells after operating iontronic devices delivering 1 for 1 h at +20 nA (Active, n = 9) and at −20 nA (Reverse, n = 11). Points represent individual biological replicates; bars indicate mean ± SD. GC growth control (untreated, n = 12). Statistical analysis was done via a Brown–Forsythe and Welch ANOVA tests (one-way) and Dunnett’s T3 multiple comparisons test. α = 0.05. p -values: GC vs. Reverse, 1 h (ns) = 0.5339; GC vs. Active, 1 h (****) = <0.0001. Certain graphical elements in ( a ) were created in BioRender. Hecko, S. (2026) https://www.BioRender.com/z8yr1eu .

Journal: Nature Communications

Article Title: Iontronic click-to-release enables electrically controlled delivery of drugs and biomolecules beyond charge and size limitations

doi: 10.1038/s41467-026-70985-0

Figure Lengend Snippet: a Schematic overview of the bioorthogonal click-to-release (C2R) cascade of CA4-prodrug: Aminoethyl tetrazine (Tz 1 ) triggers the release of the cytotoxic agent combretastatin A-4 ( CA4 ) from sulfo-cTCO-DMEDA-CA4 ( 4 ) via a tetrazine-triggered elimination from TCO caged payload and self-immolation. b Dose-dependent cell viability of human glioblastoma cell line U-87 after 72 h incubation with the key components of the C2R reaction. Data represent mean ± SD of n = 3 independent biological replicates. Curves were fit using four-parameter logistic regression. Prodrug 4 (0.01–1000 nM, grey curve); parent CA4 (0.01–1000 nM, blue curve); released CA4 (0.01–1000 nM 4 + 5 µM 1, dashed blue curve); Tz 1 (5 µM, purple data point). c Cell viability of U-87 cells after operating iontronic devices delivering 1 for 1 h at +20 nA (Active, n = 9) and at −20 nA (Reverse, n = 11). Points represent individual biological replicates; bars indicate mean ± SD. GC growth control (untreated, n = 12). Statistical analysis was done via a Brown–Forsythe and Welch ANOVA tests (one-way) and Dunnett’s T3 multiple comparisons test. α = 0.05. p -values: GC vs. Reverse, 1 h (ns) = 0.5339; GC vs. Active, 1 h (****) = <0.0001. Certain graphical elements in ( a ) were created in BioRender. Hecko, S. (2026) https://www.BioRender.com/z8yr1eu .

Article Snippet: The human GBM cell line U-87 (provided by the MUG Cell Bank, catalogue no. 300367, CLS) was cultured at 37 °C and 5% CO 2 in Eagle’s minimum essential medium (E-MEM) containing 10% fetal bovine serum (FBS), 4.5 g/L glucose, 2 mM L -glutamine, and 1% MEM Non-Essential Amino Acids.

Techniques: Incubation, Control